Pharmacologic properties of candesartan cilexetil--possible mechanisms of long-acting antihypertensive action
- PMID: 10076925
- DOI: 10.1038/sj.jhh.1000749
Pharmacologic properties of candesartan cilexetil--possible mechanisms of long-acting antihypertensive action
Abstract
Candesartan cilexetil has shown potent and long-lasting antihypertensive effects in clinical trials and in several animal models of hypertension. In spontaneously hypertensive rats, the duration of the antihypertensive effect of candesartan cilexetil was compared to those of losartan, valsartan, eprosartan, and irbesartan at the same degree of maximal blood pressure reduction. A single oral dose of candesartan cilexetil at 0.3 mg/kg reduced maximal blood pressure by about 25 mm Hg, and the antihypertensive effect of candesartan cilexetil lasted the longest, continuing for more than 1 week, without an effect on circadian rhythm. In a rabbit aortic preparation, candesartan, active form of candesartan cilexetil, decreased the maximal contractile response of angiotensin II. This inhibitory mode was different from that of other angiotensin II-receptor antagonists, and showed a shift to the right in the angiotensin II-induced contraction curve and/or a small depression of the maximal response. In kinetic studies using bovine adrenal cortical membrane and tritiated candesartan, both receptor association and dissociation were found to be slow. The dissociation rate of tritiated candesartan binding (t1/2 = 66 min) was five times slower than that of radiolabelled angiotensin II binding (t1/2 = 12 min). The insurmountable inhibition of candesartan in vascular contraction is the result of its tight binding and slow dissociation from angiotensin II AT1 receptors. These characteristics are related to the potency and long duration of action in candesartan cilexetil.
Similar articles
-
[Pharmacological profiles of candesartan cilexetil (TCV-116)].Nihon Rinsho. 1999 May;57(5):1130-6. Nihon Rinsho. 1999. PMID: 10361446 Review. Japanese.
-
Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin.Hypertension. 1999 Jun;33(6):1406-13. doi: 10.1161/01.hyp.33.6.1406. Hypertension. 1999. PMID: 10373224
-
[Candesartan cilexetil: pharmacological properties and protective effects against organ damage of a novel nonpeptide angiotensin II-receptor antagonist].Nihon Yakurigaku Zasshi. 2000 Mar;115(3):151-60. doi: 10.1254/fpj.115.151. Nihon Yakurigaku Zasshi. 2000. PMID: 10876800 Review. Japanese.
-
Candesartan cilexetil: an angiotensin II receptor blocker.Ann Pharmacother. 1999 Dec;33(12):1287-98. doi: 10.1345/aph.19005. Ann Pharmacother. 1999. PMID: 10630830 Review.
-
Persistent cardiovascular effects of chronic renin-angiotensin system inhibition following withdrawal in adult spontaneously hypertensive rats.J Hypertens. 2001 Aug;19(8):1393-402. doi: 10.1097/00004872-200108000-00007. J Hypertens. 2001. PMID: 11518847
Cited by
-
Achievements in Thermosensitive Gelling Systems for Rectal Administration.Int J Mol Sci. 2021 May 23;22(11):5500. doi: 10.3390/ijms22115500. Int J Mol Sci. 2021. PMID: 34071110 Free PMC article. Review.
-
Candesartan cilexetil: an update of its use in essential hypertension.Drugs. 2002;62(8):1253-87. doi: 10.2165/00003495-200262080-00016. Drugs. 2002. PMID: 12010090 Review.
-
Differential clinical profile of candesartan compared to other angiotensin receptor blockers.Vasc Health Risk Manag. 2011;7:749-59. doi: 10.2147/VHRM.S22591. Epub 2011 Dec 12. Vasc Health Risk Manag. 2011. PMID: 22241949 Free PMC article. Review.
-
Experimental data using candesartan and captopril indicate no double-edged sword effect in COVID-19.Clin Sci (Lond). 2021 Feb 12;135(3):465-481. doi: 10.1042/CS20201511. Clin Sci (Lond). 2021. PMID: 33479758 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials